Robert F. Kennedy Jr., confirmed as Secretary of Health and Human Services in February 2025, has not yet filed his annual financial disclosure report, drawing scrutiny from ethics watchdogs concerned about potential conflicts of interest involving pharmaceutical companies he now oversees.
The delayed filing matters because Kennedy's disclosure could reveal financial details about his involvement in ongoing litigation against Merck, one of the nation's largest vaccine manufacturers. As HHS Secretary, Kennedy now regulates the pharmaceutical industry through his control of the FDA and CDC, making any financial interests in vaccine-related cases a transparency issue.
Kennedy, who built a career challenging vaccine safety and promoting alternative medicine, has long maintained financial ties to litigation against drug manufacturers. His nonprofit group, the Children's Health Defense, has supported legal action against Merck over vaccine-related claims. Ethics officials and government watchdogs typically require senior officials to disclose income sources, investment holdings, and ongoing legal interests that could create conflicts between their personal finances and official duties.
The timing of the disclosure gap raises questions about the pace of review within the Trump administration, which confirmed Kennedy to lead HHS despite his controversial vaccine skepticism and his lack of traditional medical credentials or public health experience. His nomination faced opposition from medical organizations and public health experts who cited his promotion of discredited vaccine-autism theories.
A financial disclosure would normally show whether Kennedy received any settlements or payments from the Merck litigation, how much his organization has profited from vaccine-related legal actions, and what holdings he maintains in pharmaceutical companies or health-related investments. The report would also detail any agreements about future payments tied to litigation outcomes.
Kennedy has not disclosed the financial terms of his involvement in the Merck case or similar litigation. His previous disclosures, when he filed them as an environmental attorney and activist, showed he earned substantial income from legal settlements and nonprofit fundraising. The scale of his current financial interests remains unclear to the public and potentially to ethics officials reviewing his conflicts.
The delay in filing compounds concerns raised by ethics advocates about potential conflicts embedded in Kennedy's appointment itself. His selection to lead the agency responsible for vaccine approval and safety policy directly contradicts his public record opposing vaccine mandates and promoting baseless safety concerns about immunizations.
HHS did not provide a timeline for when Kennedy's disclosure would be submitted when contacted by reporters. Federal law requires senior officials to file annual disclosures, though enforcement varies depending on the agency and administration priorities. The Office of Government Ethics typically oversees compliance, but agencies can face pressure to move quickly when reviewing politically sensitive appointments.
Kennedy's financial report, once filed, will enter the public record and become available through the Office of Government Ethics website. Citizens, journalists, and ethics organizations can then examine the specifics of his financial interests and determine whether he has recused himself from decisions involving companies or litigation connected to his personal wealth.